The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia-Reference-Cited by-同舟云学术

The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia

Published:2023-04-04 Issue:7 Volume:58 Page:826-828
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Fernando Fiona,Innes Andrew J.^ORCID,Claudiani Simone,Pryce Angharad,Hayden Chloe,Byrne Jenny,Gallipoli Paolo,Copland Mhairi,Apperley Jane F.^ORCID,Milojkovic Dragana

Funder

Incyte

Novartis | Novartis Pharmaceuticals UK Limited

Pfizer Inc. | Pfizer UK

Astellas Pharma Europe

Jazz Pharmaceuticals

Servier

Cyclacel Ltd Incyte

Bristol-Myers Squibb

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-023-01975-9.pdf

Reference11 articles.

1. Réa D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138:2031–41. https://doi.org/10.1182/blood.2020009984.

2. Schmidt S, Liu Y, Hu ZH, Williams KM, Lazarus HM, Vij R, et al. The role of donor lymphocyte infusion (DLI) in post-hematopoietic cell transplant (HCT) relapse for chronic myeloid leukemia (CML) in the tyrosine kinase inhibitor (TKI) era. Biol Blood Marrow Transplant. 2020;26:1137–43. https://doi.org/10.1016/j.bbmt.2020.02.006.

3. DeFilipp Z, Ancheta R, Liu Y, Hu ZH, Gale RP, Snyder D, et al. Maintenance tyrosine kinase inhibitors following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia: a Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2020;26:472–9. https://doi.org/10.1016/j.bbmt.2019.10.017.

4. DeFilipp Z, Langston AA, Chen Z, Zhang C, Arellano ML, El Rassi F, et al. Does post-transplant maintenance therapy with tyrosine kinase inhibitors improve outcomes of patients with high-risk Philadelphia chromosome-positive leukemia? Clin Lymphoma Myeloma Leuk. 2016:466–71.e1. https://doi.org/10.1016/j.clml.2016.04.017.

5. Chalandon Y, Passweg JR, Guglielmi C, Iacobelli S, Apperley J, Schaap NP, et al. Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. Haematologica. 2014;99:1492–8. https://doi.org/10.3324/haematol.2013.100198.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple drugs;Reactions Weekly;2024-05-18